Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study.

Aditya Bardia Ian E Krop Takahiro Kogawa Dejan Juric Anthony W Tolcher Erika Paige Hamilton Toru Mukohara Aaron E Lisberg Toshio Shimizu Alexander I Spira Junji Tsurutani Senthil Damodaran Kyriakos P PapadopoulosJonathan GreenbergFumiaki KobayashiHong Zebger-GongRie WongYui KawasakiTadakatsu NakamuraFunda Meric-Bernstam

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)

In patients with heavily pretreated advanced HR+/HER2- BC and TNBC, Dato-DXd demonstrated promising clinical activity and a manageable safety profile. Dato-DXd is currently being evaluated in phase III studies.

Keyphrases

phase iii
open label
clinical trial
squamous cell carcinoma
small cell lung cancer
phase ii
randomized controlled trial
placebo controlled
case control
study protocol